Tumors: Too sweet to remember?

Parham P: Innate immunity: The unsung heroes. Nature. 2003, 423 (6935): 20. 10.1038/423020a Vollmers HP, Brandlein S: The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol. 2005, 20 (3): 927-937. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol. 2001, 1 (2): 135-145. 10.1038/35100529 Medzhitov R, Janeway CA: Decoding the patterns of self and nonself by the innate immune system. Science. 2002, 296 (5566): 298-300. 10.1126/science.1068883 Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 2003, 63 (22): 7995-8005. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemont N, Delneste Y: Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood. 2004, 104 (6): 1778-1783. 10.1182/blood-2003-08-2820 Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124 (4): 783-801. 10.1016/j.cell.2006.02.015 Kaisho T, Akira S: Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006, 117 (5): 979-87; quiz 988. 10.1016/j.jaci.2006.02.023 Gay NJ, Gangloff M, Weber AN: Toll-like receptors as molecular switches. Nat Rev Immunol. 2006, 6 (9): 693-698. 10.1038/nri1916 Pasare C, Medzhitov R: Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005, 560: 11-18. Klein J: Private and public antigens of the mouse H-2 system. Nature. 1971, 229 (5287): 635-637. 10.1038/229635a0 Benacerraf B, McDevitt HO: Histocompatibility-linked immune response genes. Science. 1972, 175 (19): 273-279. 10.1126/science.175.4019.273 Zinkernagel RM, Doherty PC: The discovery of MHC restriction. Immunol Today. 1997, 18 (1): 14-17. 10.1016/S0167-5699(97)80008-4 Snell GD: The immunogenetics of tumor transplantation. Cancer Res. 1952, 12 (8): 543-546. Dausset J: [Iso-leuko-antibodies.]. Acta Haematol. 1958, 20 (1-4): 156-166. Fuster MM, Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005, 5 (7): 526-542. 10.1038/nrc1649 Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, Ishikawa H: Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol. 2002, 34 (4): 408-415. 10.1097/00004836-200204000-00005 Satoh H, Ishikawa H, Yamashita YT, Takahashi H, Ishikawa S, Kamma H, Ohtsuka M, Hasegawa S: Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer. Anticancer Res. 1998, 18 (4B): 2865-2868. Hayashi N, Nakamori S, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Narimatsu H, Monden M: Association between expression levels of CA 19-9 and N-acetylglucosamine-beta;1, 3-galactosyltransferase 5 gene in human pancreatic cancer tissue. Pathobiology. 2004, 71 (1): 26-34. 10.1159/000072959 Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 2003, 22 (9): 1324-1332. 10.1038/sj.onc.1206291 Kobata A, Amano J: Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol. 2005, 83 (4): 429-439. 10.1111/j.1440-1711.2005.01351.x Nakamura K, Tanaka Y, Shitara K, Hanai N: Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother. 2001, 50 (5): 275-284. 10.1007/PL00006689 Fredman P, Hedberg K, Brezicka T: Gangliosides as therapeutic targets for cancer. BioDrugs. 2003, 17 (3): 155-167. 10.2165/00063030-200317030-00002 Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M: ABH and Lewis histo-blood group antigens in cancer. Apmis. 2001, 109 (1): 9-31. 10.1111/j.1600-0463.2001.tb00011.x Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002, 99 (16): 10231-10233. 10.1073/pnas.172380699 Dube DH, Bertozzi CR: Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005, 4 (6): 477-488. 10.1038/nrd1751 Macario AJ, Conway de Macario E: Sick chaperones, cellular stress, and disease. N Engl J Med. 2005, 353 (14): 1489-1501. 10.1056/NEJMra050111 Hendershot LM: The ER function BiP is a master regulator of ER function. Mt Sinai J Med. 2004, 71 (5): 289-297. Misra UK, Gonzalez-Gronow M, Gawdi G, Pizzo SV: The role of MTJ-1 in cell surface translocation of GRP78, a receptor for alpha 2-macroglobulin-dependent signaling. J Immunol. 2005, 174 (4): 2092-2097. Delpino A, Piselli P, Vismara D, Vendetti S, Colizzi V: Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin. Mol Membr Biol. 1998, 15 (1): 21-26. Ma Y, Hendershot LM: The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer. 2004, 4 (12): 966-977. 10.1038/nrc1505 Zhai L, Kita K, Wano C, Wu Y, Sugaya S, Suzuki N: Decreased cell survival and DNA repair capacity after UVC irradiation in association with down-regulation of GRP78/BiP in human RSa cells. Exp Cell Res. 2005, 305 (2): 244-252. 10.1016/j.yexcr.2005.01.002 Li J, Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006, 6 (1): 45-54. 10.2174/156652406775574523 Rauschert N, Brandlein S, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2007 Hensel F, Hermann R, Schubert C, Abe N, Schmidt K, Franke A, Shevchenko A, Mann M, Muller-Hermelink HK, Vollmers HP: Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 1999, 59 (20): 5299-5306. Hensel F, Brandlein S, Eck M, Schmidt K, Krenn V, Kloetzer A, Bachi A, Mann M, Muller-Hermelink HK, Vollmers HP: A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest. 2001, 81 (8): 1097-1108. Brandlein S, Beyer I, Eck M, Bernhardt W, Hensel F, Muller-Hermelink HK, Vollmers HP: Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res. 2003, 63 (9): 2052-2061. Slovin SF, Keding SJ, Ragupathi G: Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol. 2005, 83 (4): 418-428. 10.1111/j.1440-1711.2005.01350.x Chen S, Fukuda M: Cell type-specific roles of carbohydrates in tumor metastasis. Methods Enzymol. 2006, 416: 371-380. 10.1016/S0076-6879(06)16024-3 Zilka A, Landau G, Hershkovitz O, Bloushtain N, Bar-Ilan A, Benchetrit F, Fima E, van Kuppevelt TH, Gallagher JT, Elgavish S, Porgador A: Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry. 2005, 44 (44): 14477-14485. 10.1021/bi051241s Aarnoudse CA, Garcia Vallejo JJ, Saeland E, van Kooyk Y: Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol. 2006, 18 (1): 105-111. 10.1016/j.coi.2005.11.001 Ragupathi G, Koide F, Livingston PO, Cho YS, Endo A, Wan Q, Spassova MK, Keding SJ, Allen J, Ouerfelli O, Wilson RM, Danishefsky SJ: Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J Am Chem Soc. 2006, 128 (8): 2715-2725. 10.1021/ja057244+ Gilboa E: The promise of cancer vaccines. Nat Rev Cancer. 2004, 4 (5): 401-411. 10.1038/nrc1359 Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ: Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003, 9 (14): 5214-5220. Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudryashov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ: Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad Sci U S A. 2000, 97 (6): 2719-2724. 10.1073/pnas.97.6.2719 Hensel F, Knorr C, Hermann R, Krenn V, Muller-Hermelink HK, Vollmers HP: Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Int J Cancer. 1999, 81 (2): 229-235. 10.1002/(SICI)1097-0215(19990412)81:2<229::AID-IJC11>3.0.CO;2-U Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, Reindl L, Muller-Hermelink HK: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep. 1998, 5 (3): 549-552. Pohle T, Brandlein S, Ruoff N, Muller-Hermelink HK, Vollmers HP: Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 2004, 64 (11): 3900-3906. 10.1158/0008-5472.CAN-03-3149 Brändlein S: The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol Cancer Ther. 2007, 6 (1): 326-333. 10.1158/1535-7163.MCT-06-0399